• Rivankar, S. (2014). An overview of doxorubicin formulations in cancer therapy. Journal of cancer research and therapeutics, 10(4), 853-858.
• Vigevani, A., & Williamson, M. J. (1981). Doxorubicin. In Analytical profiles of drug substances (Vol. 9, pp. 245-274). Academic Press.
• Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clinical pharmacokinetics, 42(5), 419-436.
• Ansari, L., Shiehzadeh, F., Taherzadeh, Z., Nikoofal-Sahlabadi, S., Momtazi-Borojeni, A. A., Sahebkar, A., & Eslami, S. (2017). The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials. Cancer gene therapy, 24(5), 189-193.